Scott Loughhead

Scott Loughhead

Company: SQZ Biotechnologies

Job title: Senior Director of Immuno-Oncology Research


Novel Cell Therapy Method to Generate Antigen Presenting Cells for Multiple KRAS Mutations 12:30 pm

SQZ APC mechanism overcomes challenges of previous cancer vaccines with CD8 T-cell activation and can be enhanced with mRNA cargo combinations SQZ APC clinical program overview: Safety and manufacturability of SQZ’s APC candidate in solid tumors Preclinical data for SQZ’s enhanced APC platform in targeting KRAS G12D and G12V mutationRead more

day: Day One Track C

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.